No. |
DrugBank |
薬物名(臨床試験情報から抽出) |
KEGG DRUG * | KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 | Cidofovir | 1件: Cidofovir; | D00273 |
- |
- |
1件: 25 |
2 | Cytarabine | 2件: Carmustine, etoposide, cytarabine, and melphalan (beam); Cytarabine; | D00168 D03046 D03637 |
- |
- |
6件: 11, 13, 14, 25, 49, 60 |
3 | Didanosine | 1件: Didanosine; | D00296 |
- |
- |
2件: 25, 265 |
4 | Emtricitabine | 5件: Emtricitabine; Emtricitabine (ftc)/tenofovir disoproxil (tdf); Emtricitabine/tenofovir; Tenofovir (tdf) and emtricitabine (ftc); Tenofovir-emtricitabine; | D01199 |
- |
- |
4件: 25, 93, 265, 325 |
5 | Enfuvirtide | 2件: Enfuvirtide; Enfuvirtide (t20); | D02499 |
- |
- |
2件: 25, 265 |
6 | Filgrastim | 6件: Ep2006 (filgrastim); Filgrastim; Filgrastim (g-csf); Filgrastim hexal; Filgrastim, alemtuzumab; Granulocyte colony-stimulating factor (filgrastim); | D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
7 | Interferon alfa | 5件: Interferon alfa; Interferon alfa-2a; Interferon alfa-2b; Pegylated interferon alfa; Recombinant interferon alfa; | D03305 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
5件: 25, 26, 28, 56, 96 |
8 | Interferon alfa-2b | 1件: Interferon alfa-2b; | D02745 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
3件: 25, 34, 227 |
9 | Interleukin-7 | 2件: Interleukin-7; Recombinant human interleukin-7; | - |
- |
- |
1件: 25 |
10 | Mefloquine | 1件: Mefloquine; | D04895 |
- |
- |
1件: 25 |
11 | Methylprednisolone | 29件: Administration of rituximab and methylprednisolone; Corticosteroid treatment (methylprednisolone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Infliximab, methylprednisolone, methotrexate; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methotrexate + methylprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone (mp); Methylprednisolone (mp) or prednisone (pred); Methylprednisolone (or other glucocorticoid); Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone mylan générique; Methylprednisolone or budesonide; Methylprednisolone or prednisolone; Methylprednisolone pulse; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides; | D00407 D00751 D00979 D05000 D05001 D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
12 | Natalizumab | 12件: Bg00002 (natalizumab); Bg00002-e (natalizumab high titer); Bg0002 (natalizumab); Natalizumab; Natalizumab (bg00002); Natalizumab (ntz); Natalizumab (tysabri); Natalizumab for iv infusion; Natalizumab for subcutaneous injection; Natalizumab treatment; Tysabri ® (natalizumab); Tysabri® (natalizumab); | D06886 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
6件: 13, 15, 25, 46, 63, 96 |
13 | Pembrolizumab | 1件: Pembrolizumab; | D10574 |
1件: PDCD1 |
3件: Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway |
1件: 25 |
14 | Prednisolone | 46件: Azd4017 and prednisolone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroid (prednisolone); Corticosteroid treatment (methylprednisolone or prednisolone); Corticosteroids (prednisone or prednisolone); Etanercept, methotrexate, prednisolone; Glucocorticoid (prednisone or prednisolone); Intravenous methyl prednisolone; Long-circulating liposomal prednisolone; Low dose prednisolone; Medium dose prednisolone; Methotrexate - etanercept - prednisolone arm; Methyl prednisolone; Methylprednisolone or prednisolone; Oral prednisolone; Overencapsulated prednisolone tablets; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Peg-liposomal prednisolone sodium phosphate; Prednisolone; Prednisolone & dipyridamole; Prednisolone + mabthera; Prednisolone 1mg tablets; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone 5mg tablet; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil; Prednisolone and taper; Prednisolone sodium metasulphobenzoate; Prednisolone sodium phosphate; Prednisolone sodium succinate; Prednisolone tablets b.p. 5mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Prednisone or prednisolone; Prednisone/prednisolone; Pyridoxine plus prednisolone; Soluble prednisolone tablets; Sulphasalazine + hydroxychloroquine or prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Z102 (prednisolone and dipyridamole).; | D00472 D00980 D00981 D00982 D01239 D01998 D02156 D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
15 | Probenecid | 1件: Probenecid; | D00475 |
- |
- |
1件: 25 |
16 | Tenofovir | 10件: Emtricitabine (ftc)/tenofovir disoproxil (tdf); Emtricitabine/tenofovir; Tenofovir; Tenofovir (tdf) and emtricitabine (ftc); Tenofovir alafenamide; Tenofovir alafenamide (taf); Tenofovir df; Tenofovir disoproxil; Tenofovir disoproxil fumarate; Tenofovir-emtricitabine; | D06074 |
- |
- |
5件: 2, 25, 93, 265, 325 |
17 | Teriflunomide | 6件: Teriflunomide; Teriflunomide (hmr1726); Teriflunomide 14 mg; Teriflunomide 14 mg oral tablet [aubagio]; Teriflunomide hmr1726; Teriflunomide orally; | D10172 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
2件: 13, 25 |
18 | Topotecan | 1件: Topotecan; | D02168 D08618 |
- |
- |
1件: 25 |
19 | Zalcitabine | 1件: Zalcitabine; | D00412 |
- |
- |
1件: 25 |
20 | Zidovudine | 8件: Abacavir sulfate, lamivudine and zidovudine; Combivir (zidovudine [azt] / lamivudine [3tc]); Lamivudine/zidovudine; Lopinavir/ritonavir + zidovudine + lamivudine; Raltegravir and zidovudine; Reverse transcriptase inhibitors: zidovudine, lamivudine, abacavir; Zidovudine; Zidovudine/lamivudine; | D00413 |
- |
- |
6件: 25, 26, 135, 265, 325, 331 |